Last reviewed · How we verify
TriMaximize: A Multicentre, Prospective, Non-interventional Trial Monitoring Therapy Pathways of Asthma Patients Treated With an Extra-fine ICS/LABA/LAMA Single-inhaler Triple Therapy in a Real-world Setting and Characterizing the Effects on Health-related Outcomes. (Trimaximize PL)
TriMaximize: A multicentre, prospective, non-interventional trial monitoring therapy pathways of asthma patients treated with an extra-fine ICS/LABA/LAMA single-inhaler triple therapy in a real-world setting and characterizing the effects on health-related outcomes.
Details
| Lead sponsor | Chiesi Poland Sp. z o.o. |
|---|---|
| Status | RECRUITING |
| Enrolment | 60 |
| Start date | 2024-08 |
| Completion | 2025-08-01 |
Conditions
- Asthma
Interventions
- Trimbow
Primary outcomes
- The primary objective is to describe patient characteristics and therapy path-ways for patients with a diagnosis of moderate to severe asthma who are treated with Trimbow in real world practice. — 12 months
Primary outcome measures include: Descriptive analisys of patients demografic Descriptive analisys of patient demographic
Countries
Poland